	US 11,897,942 B2
	Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies
Cagla Tukel Wilson, Huntingdon Valley, PA (US); and Scott Dessain, Wynnewood, PA (US)
Assigned to Temple University—Of The Commonwealth System of Higher Education, Philadelphia, PA (US); and LANKENAU INSTITUTE OF MEDICAL RESEARCH, Wynnewood, PA (US)
Appl. No. 17/058,575
Filed by Temple University—Of The Commonwealth System of Higher Education, Philadelphia, PA (US); and LANKENAU INSTITUTE OF MEDICAL RESEARCH, Wynnewood, PA (US)
PCT Filed May 24, 2019, PCT No. PCT/US2019/033897 § 371(c)(1), (2) Date Nov. 24, 2020, PCT Pub. No. WO2019/226978, PCT Pub. Date Nov. 28, 2019.
Claims priority of provisional application 62/676,390, filed on May 25, 2018.
Prior Publication US 2021/0122809 A1, Apr. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/12 (2006.01); A61P 31/04 (2006.01)

CPC C07K 16/1235 (2013.01) [A61P 31/04 (2018.01); C07K 16/1228 (2013.01); C07K 16/1232 (2013.01)]

20 Claims

1. A composition comprising a therapeutic antibody, wherein the antibody is specific for binding to an epitope of curli and further wherein the epitope of curli comprises a sequence having homology to an antibody binding site of one or more heterologous amyloid proteins;

wherein the antibody is a monoclonal antibody selected from the group consisting of:

a) ALZ.3H3, comprising at least one heavy chain amino acid sequence as set forth in SEQ ID NO:2 and at least one light chain amino acid sequence as set forth in SEQ ID NO:35;

b) ALZ.4G1, comprising at least one heavy chain amino acid sequence as set forth in SEQ ID NO:61 and at least one light chain amino acid sequence as set forth in SEQ ID NO:63; and

c) ALZ.4A6, comprising at least one of a heavy chain amino acid sequence as set forth in SEQ ID NO:57 and at least one light chain amino acid sequence as set forth in SEQ ID NO:59.